Hypercoagulability during induction therapy of acute lymphoblastic leukemia is of scarce clinical relevance. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto.
de Stefano
V
V
Gugliotta
L
L
Mazzucconi
M G
MG
Leone
G
G
Mandelli
F
F
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000990:Antithrombin III / Q000032:analysis; D001215:Asparaginase / Q000008:administration & dosage; D001777:Blood Coagulation / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005340:Fibrinogen / Q000378:metabolism; D005341:Fibrinolysin / Q000032:analysis; D005344:Fibrinopeptide A / Q000032:analysis; D006801:Humans; D010447:Peptide Hydrolases / Q000032:analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D011446:Prospective Studies; D011516:Prothrombin / Q000032:analysis; D014750:Vincristine / Q000008:administration & dosage; D000979:alpha-2-Antiplasmin / Q000032:analysis
D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; D005344:Fibrinopeptide A; D014750:Vincristine; D003520:Cyclophosphamide; D000990:Antithrombin III; D011516:Prothrombin; D005340:Fibrinogen; D010447:Peptide Hydrolases; D005341:Fibrinolysin; D001215:Asparaginase; D011241:Prednisone; D003630:Daunorubicin